Cancer Biology & Therapy 13:8, 586-587; June 2012; © 2012 Landes Bioscience
Angiogenesis inhibitors increase tumor stem cells Cindy H. Chau and William D. Figg* Molecular Pharmacology Section; Medical Oncology Branch; Center for Cancer Research; National Cancer Institute; Bethesda, MD USA
T
he clinical efficacy of angiogenesis inhibitors targeting the vascular endothelial growth factor pathway has recently been met with numerous phase III failures that showed modest survival benefits. Understanding the resistance mechanisms of antiangiogenic therapy is essential to overcoming the limited effectiveness of VEGF-pathway inhibitors. A recent study published in the Proceedings of the National Academy of Sciences provides a novel explanation to the treatment limitations of angiogenesis inhibitors and suggests a potential strategy to improve the clinical utility of these agents.
bevacizumab in solid tumors only three were positive for overall survival (first-line mCRC,2 second-line mCRC3 and firstline recurrent/advanced NSCLC4). In 2011, this concern made headlines when FDA rescinded the approval of bevacizumab for the treatment of breast cancer following the failure of two phase III clinical trials to demonstrate an improvement in overall survival for first-line breast carcinoma.5,6 Emerging clinical and preclinical evidence suggested that the limited efficacy observed with angiogenesis inhibitors arise from tumors eliciting evasive resistance to these regimens. Interestingly, recent studies in preclinical models have demonstrated an increase in tumor invasiveness and metastasis in response to VEGF-targeted therapies or VEGF gene inactivation.7-9 Angiogenesis inhibitors often cause tumor vessels to regress resulting in vessel normalization. This vascular pruning can also cause intratumoral hypoxia, which in turn activates the hypoxia-inducible 1 factor α (HIF-1α) and HIF-mediated pathways to promote invasion and metastasis from the tumor.10 Moreover, several reports have implicated a critical role for hypoxia and HIF in cancer stem cell (CSC) proliferation, self-renewal and maintanence.11 The tumor-initiating properties and metastatic potential of CSCs make them key drivers of tumor growth and therapy resistance. In the recent study published in the Proceedings of the National Academy of Sciences, Conley and colleagues hypothesized that hypoxia induced by the administration of angiogenesis inhibitors might accelerate tumor growth and metastasis by increasing the CSC population.12
© 2012 Landes Bioscience. Do not distribute. Angiogenesis Inhibitors Increase Tumor Stem Cells
Keywords: angiogenesis, tumor hypoxia, cancer stem cells Submitted: 02/17/12 Accepted: 02/28/12 http://dx.doi.org/10.4161/cbt.19852 *Correspondence to: William D. Figg; Email:
[email protected]
586
Since 1971, the angiogenic pathway has been a valid target for anticancer drug development. Dr Folkman theorized that a tumor was dependent on the recruitment of blood vessels in order to grow and by blocking this process one could inhibit the progression.1 This basic idea led to the investigation of hundreds of potential angiogenesis inhibitors, with bevacizumab [vascular endothelial growth factor (VEGF) neutralizing antibody] being the first agent to gain FDA approval. This was followed by the approval of several VEGF receptor tyrosine kinase inhibitors (sorafenib, sunitinib, pazopanib and axitinib) that targeted different parts of the angiogenic pathway. Nonetheless, clinical experience with bevacizumab has proven to be rather perplexing for most oncologists (improvement in progression free survival, but little to no benefit in overall survival). In fact, of the 16 pivotal phase III trials conducted with
Cancer Biology & Therapy
Volume 13 Issue 8
Journal Club
Using breast cancer xenograft models and the Aldefluor assay to identify the CSC population, they showed that by generating intratumoral hypoxia with sunitinib malate and bevacizumab, this resulted in an increase in the population of cancer stem cells. Concentrated populations of CSCs were predominantly localized in hypoxic regions within tumors from drugtreated mice. Human breast cancer cell lines grown in vitro under mild hypoxic conditions also resulted in an expansion of the CSC population. Furthermore, it was shown that HIF-1α was primarily responsible for the stem cell enrichment and that the hypoxia-induced increase in the CSC population was mediated through activation of the AKT/β-catenin regulatory pathway.
Taken together, these findings suggest that antiangiogenic therapy leads to the generation of tumor hypoxia and results in an increase in the CSC population. This CSC niche may be responsible for mediating tumor metastasis and resistance to cancer treatments. These studies may help explain the limited clinical utility of angiogenesis inhibitors and add another dimension to the existing modes of resistance to angiogenesis inhibitors that already involve complex tumor and hostmediated pathways.13,14 Understanding the mechanisms of resistance is essential for developing strategies that will allow for optimal exploitation of the potential of angiogenesis inhibitors. Data from the current study have tremendous clinical implications and reveal a new approach
to overcome resistance to antiangiogenic agents by targeting the cancer stem cell population. Clinically, angiogenesis agents have a role, albeit often transient and patients relapse with more invasive metastatic disease resulting in minimal overall survival advantage. If we could identify a cancer stem cell-targeting agent and combine it with an angiogenesis inhibitor, we might develop a synergistic combination that represents an improved therapeutic regimen with better clinical efficacy. Acknowledgments
This work was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health.
© 2012 Landes Bioscience. References
1. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133:275-88; PMID:4332371; http://dx.doi.org/10.1084/jem.133.2.275. 2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:233542; PMID:15175435; http://dx.doi.org/10.1056/ NEJMoa032691. 3. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, et al.; eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539-44; PMID:17442997; http:// dx.doi.org/10.1200/JCO.2006.09.6305. 4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50; PMID:17167137; http://dx.doi.org/10.1056/NEJMoa061884. 5. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28:3239-47; PMID:20498403; http://dx.doi.org/10.1200/JCO.2008.21.6457.
6. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29:125260; PMID:21383283; http://dx.doi.org/10.1200/ JCO.2010.28.0982. 7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:2329; PMID:19249681; http://dx.doi.org/10.1016/j. ccr.2009.01.021. 8. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31; PMID:19249680; http://dx.doi. org/10.1016/j.ccr.2009.01.027. 9. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15:16770; PMID:19249675; http://dx.doi.org/10.1016/j. ccr.2009.02.007.
10. De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 2011; 8:393-404; PMID:21629216; http://dx.doi.org/10.1038/nrclinonc.2011.83. 11. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102:789-95; PMID:20104230 ; http://dx.doi.org/10.1038/ sj.bjc.6605551. 12. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 2012; 109:2784-9; PMID:22308314; http://dx.doi. org/10.1073/pnas.1018866109. 13. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008; 8:592603; PMID:18650835; http://dx.doi.org/10.1038/ nrc2442. 14. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009; 15:5020-5; PMID:19671869; http://dx.doi. org/10.1158/1078-0432.CCR-09-0095.
Do not distribute.
www.landesbioscience.com
Cancer Biology & Therapy
587
